Navigation Links
Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
Date:10/27/2008

urthermore, it had similar efficacy to orally administered diclofenac with fewer gastrointestinal, hepatic and renal adverse events. Topical NSAIDs should be considered in the management of patients with symptomatic osteoarthritis involving joints accessible to these agents."

Nuvo's Phase III trial, Study 112, enrolled 775 patients in the U.S. and Canada with symptoms of primary osteoarthritis of the knee. Patients in this five-arm, double-blind, 12-week trial applied a topical solution and took an oral pill. The five arms were: 1) Pennsaid(R) plus oral placebo, 2) topical placebo containing a small amount of DMSO for blinding purposes (DMSO facilitates delivery of diclofenac to the knee) plus oral placebo, 3) topical vehicle-control (containing the same concentration of DMSO as in Pennsaid(R)) plus oral placebo, 4) topical placebo plus oral diclofenac and 5) Pennsaid(R) plus oral diclofenac.

Pennsaid(R) (arm 1) was superior to placebo (arm 2) with statistically significant improvement in all three primary clinical endpoints required by the FDA: pain relief (p=0.019), improvement in physical function (p=0.046) and improved patient overall health assessment (POHA) (p less than 0.0001).

Additional results from the trial show that Pennsaid(R) (arm 1) was superior to vehicle control (arm 3) (pain, p=0.009; physical function, p=0.026; POHA, p=0.016). There was no difference between vehicle control (arm 3) and placebo (arm 2) indicating that DMSO alone is ineffective against the symptoms of knee osteoarthritis (p greater than 0.05). There was no difference between Pennsaid(R) (arm 1) and oral diclofenac (arm 4) for all three endpoints (p greater than 0.05). Arm 5 was included in the trial at the FDA's request to review the side effect profile of Pennsaid(R) if combined with an oral NSAID. This combination showed no increased incidence of the usual side effects, just the expected additive profiles of Pennsaid(R) alone plus oral diclofenac alone.

'/>"/>
SOURCE Nuvo Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Alzheimers Association Grant Furthers Successful Research at UMass Lowell
2. Local Research Foundation Achieves Milestone in Fight Against Cancer
3. Congresswoman Supporting Spinal Cord Research Intended to Benefit U.S. Veterans
4. American College of Cardiology and Center of Excellence for Simulation Research of Western Michigan University (CESR) Partner for in situ Simulation to Improve Team Communication and Door-to-Balloon (D2B) Time
5. Susan G. Komen for the Cure(R) Makes Unprecedented Research and Local Program Grants
6. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
7. Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing
8. Wild Blueberries Take Top Spot in New Antioxidant Research Study
9. Research Attributes Lack of HIV/AIDS Vaccine to Use of Chimpanzees
10. Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children
11. Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics miRview(TM) Squamous Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Inc. (OTC Bulletin Board: HEWA) an online U.S. mail-order ... 12% per annum short term debt financing. The ... of $500,000, with accrued interest and principal repayable in ... interest and principal repayable in one year from its ... for any calendar month prior to December 15, 2010. ...
(Date:12/16/2009)... AVAX Technologies, Inc. (Pink Sheets: AVXT) ("AVAX" or ... a bridge loan financing (the "2009 Financing") pursuant ... (the "Agreement") with Firebird Global Master Fund, Ltd., ... a convertible promissory note, due June 30, 2010, ... issued a warrant to purchase an aggregate of ...
(Date:12/16/2009)... Inc. today announced the treatment of the first ... adhesive product, TissuGlu®. Initiation of the study marks ... the lead product toward clinical practice. ,, ... study to investigate the safety of TissuGlu and ... in abdominoplasty, or "tummy tuck," surgeries. The study ...
Breaking Medicine Technology:HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2AVAX Technologies, Inc. Closes Bridge Financing 2AVAX Technologies, Inc. Closes Bridge Financing 3AVAX Technologies, Inc. Closes Bridge Financing 4First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3Valeritas Announces Appointment of New CEO 12391 1Valeritas Announces Appointment of New CEO 12391 2Valeritas Announces Appointment of New CEO 12391 317 million US children live more than an hour away from trauma care 47486 117 million US children live more than an hour away from trauma care 47486 2Temporary infidelity may contribute to the stability of ancient relationships 8678 1
... Cardiovascular, Research Foundation,s ADAPT-DES Study to Quantify Causes and Cures of ... ... Volcano Corporation,(Nasdaq: VOLC ) [TCT Booth #2013 Level 2], a ... its sponsorship of the first major study designed to,examine the role ...
... TUSTIN, Calif., Oct. 22 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... monoclonal antibodies for the treatment of cancer and,hepatitis ... has submitted a,Phase II clinical protocol with the ... study bavituximab in combination with the chemotherapy drug,docetaxel ...
Other Medicine Technology:Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome 2Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome 3Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome 4Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 2Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 3Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 4
(Date:12/16/2009)... For wounded U.S. servicemen and women recovering at ... holidays can be a particularly difficult time. Wounded ... than ever on the healing power of connecting with ... got easier for Walter Reed patients as Verizon Wireless ... hundreds of minutes of holiday talk time for 2,500 ...
(Date:12/16/2009)... 16 HealthSciences Institute will sponsor ... professionals, teams and organizations who serve individuals ... diseases in employer, health plan, medical home ... will offer free, noncommercial webinars on topics, ... prevention, management and care improvement. Each webinar ...
(Date:12/16/2009)... role in reducing inflammation in the lungs , , WEDNESDAY, ... plays a role in inflammation seems to protect the ... who smoke. , Researchers also found that adult smokers ... lower risk of developing chronic obstructive pulmonary disease (COPD), ... "The gene seems to be protective of the lungs ...
(Date:12/16/2009)... work on a malaria elimination study in Africa have ... disease using cell phone records. , The scientists analyzed ... residents of Zanzibar travel and where they go. A ... of Tanzania in East Africa, Zanzibar has drastically reduced ... as part of deliberations on whether to launch a ...
(Date:12/16/2009)... Encourage Access to Quality, Cost-Effective Care , ... Washington, ... have debated the best ways to rein in runaway costs while ... An important part of the ongoing discussion includes how to ensure ... besides doctors of medicine (MDs) or osteopathy (DOs). In both ...
Breaking Medicine News(10 mins):Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3Health News:Gene Variant Seems to Guard Against Asthma, COPD 2Health News:Gene Variant Seems to Guard Against Asthma, COPD 3Health News:Scientists use cell phone records to predict spread of malaria 2Health News:Scientists use cell phone records to predict spread of malaria 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5
... Group, a life science-focused strategic communications agency, announced today ... sciences agency client roster.Donna L. LaVoie, President & CEO ... working on the leading edge of the life sciences ... therapeutics for complex central nervous system disorders, Mithridion,s strategy ...
... ... CA (Vocus) May 4, 2009 -- Today ADVANCE for Nurses Magazine named ... "Best Nursing Team." The award was announced in a cover story ... recognition for one of our top nursing teams," said Beverly Hayden-Pugh, Vice ...
... to urgency in preventing stroke and supporting 6 million stroke survivors in ... ... nearly 795,000 people will have a stroke, leaving a path of destruction ... National Stroke Association , which is observing National Stroke Awareness Month in ...
... federal complaint today seeking an injunction against the FDA , ... Tampa, ... a federal complaint today seeking an injunction against the FDA with respect ... The company believes the use of inhaled nicotine in a form and ...
... telephone based triage and health advice to EosHealth service subscribers ... EosHealth subscribers manage their health through interactive resources via their ... triggers and proactively reach out to perform triage and provide ... ...
... very early in Alzheimer,s disease, people become less efficient ... study has found. , Knowing this, clinicians may ... of Alzheimer,s to remember high-value information better, according to ... , published by the American Psychological Association. , ...
Other Medicine News:Health News:LaVoie Group Appointed by Mithridion as PR Agency 2Health News:Children's Hospital NICU Nurses Recognized 2Health News:Children's Hospital NICU Nurses Recognized 3Health News:Children's Hospital NICU Nurses Recognized 4Health News:Four of Five Families Will Be Touched by Stroke in 2009 2Health News:Press Release: Electronic Cigarette VS FDA 2Health News:SironaHealth to Provide 24 x 7 Nurse Line and Clinical Outreach to EosHealth as part of their Mobile Health & Wellness Programs 2Health News:SironaHealth to Provide 24 x 7 Nurse Line and Clinical Outreach to EosHealth as part of their Mobile Health & Wellness Programs 3Health News:Memory grows less efficient very early in Alzheimer's disease 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 8 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 17.0 mm and length 21 mm....
The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte...
IDS Rapid Yeast Plus, a microbial identification system....
Medicine Products: